| Předmět: |
|
| Zdroj: |
Cancer Vaccine Week; 7/15/2024, p36-36, 1p |
| Abstrakt: |
Researchers at Anhui University in the People's Republic of China have developed nanobodies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1) for cancer diagnosis and therapy. The researchers immunized alpacas with ROR1 and used their blood to extract RNA and amplify the VHH sequence. They then constructed a phage library and identified a high-affinity nanobody, HCAbs1, which effectively binds to ROR1. Functional tests showed that HCAbs1 could reduce extracellular signal-regulated kinase (ERK) phosphorylation levels induced by Wnt5a in ROR1-transfected cells. The researchers concluded that HCAbs1 nanobodies have potential in diagnosing and treating cancers by targeting ROR1. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
